Tanner, Caroline M.
Caroff, Stanley N.
Cutler, Andrew J.
Lenderking, William R.
Shalhoub, Huda
Pagé, Véronique
Franey, Ericha G.
Serbin, Michael
Yonan, Chuck
Article History
Received: 6 April 2022
Accepted: 16 January 2023
First Online: 9 March 2023
Declarations
:
: All patients provided written and informed consent for participation in the study. For all participating study sites, protocol and ethics approvals were provided by Quorum Review IRB (Seattle, WA).
: Not applicable.
: CMT receives grants from the Michael J. Fox Foundation, the Parkinson’s Foundation, the Department of Defense, BioElectron, Roche/Genentech, Biogen, and the National Institutes of Health, compensation for serving on Data Monitoring Committees from Biotie Therapeutics, Voyager Therapeutics and Intec Pharma and personal fees for consulting from Neurocrine Biosciences, Adamas Therapeutics, Biogen, 23andMe, Alexza, Grey Matter, Acadia and CNS Ratings. SNC has served as a consultant to Neurocrine Biosciences, Inc., Teva Pharmaceuticals Industries, Ltd., Osmotica Pharmaceuticals and Dispersol Technologies, and received separate research grants from Neurocrine Biosciences, Inc., Pfizer, Inc., and Eagle pharmaceuticals. AJC has served as a consultant to, received research grants from, and is on the speaker bureau for ACADIA, Avanir, Neurocrine, Otsuka and Teva, is a consultant to MedAvante-Prophase, and is on the Board of the Neuroscience Research Institute. WRL is a current full-time employee of Evidera. HS and VP are former employees of Evidera. Evidera employees served as consultants on this work. EGF, MS, and CY are full-time employees of Neurocrine Biosciences, Inc.